References

Global Health Observatory. World Health Organ. 2019. https://www.who.int/health-topics/depression. Accessed 8 May 2025. 1.

James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789–858.

Google Scholar 1.

Tylee A, Walters P. Onset of action of antidepressants. BMJ. 2007;334:911–2.

Google Scholar 1.

Miller BR, Hen R. The current state of the neurogenic theory of depression and anxiety. Curr Opin Neurobiol. 2015;30:51–8.

Google Scholar 1.

Jacobs BL, van Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry. 2000;5:262–9.

Google Scholar 1.

Tunc-Ozcan E, Peng C-Y, Zhu Y, Dunlop SR, Contractor A, Kessler JA. Activating newborn neurons suppresses depression and anxiety-like behaviors. Nat Commun. 2019;10:3768.

Google Scholar 1.

Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci Off J Soc Neurosci. 2000;20:9104–10.

Google Scholar 1.

Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805–9.

Google Scholar 1.

Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem. 2000;75:1729–34.

Google Scholar 1.

Son H, Yu IT, Hwang S-J, Kim JS, Lee S-H, Lee Y-S, et al. Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J Neurochem. 2003;85:872–81.

Google Scholar 1.

Clarke M, Razmjou S, Prowse N, Dwyer Z, Litteljohn D, Pentz R, et al. Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes. Neuropharmacology. 2017;112:210–20.

Google Scholar 1.

Arrabal-Gómez C, Serrano-Castro P, Sánchez-Pérez JA, Garcia-Casares N, Fuxe K, Borroto-Escuela D, et al. Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus. Expert Opin Ther Targets. 2024;28:309–22.

Google Scholar 1.

Madsen TM, Treschow A, Bengzon J, Bolwig TG, Lindvall O, Tingström A. Increased neurogenesis in a model of electroconvulsive therapy. Biol Psychiatry. 2000;47:1043–9.

Google Scholar 1.

Scott BW, Wojtowicz JM, Burnham WM. Neurogenesis in the dentate gyrus of the rat following electroconvulsive shock seizures. Exp Neurol. 2000;165:231–6.

Google Scholar 1.

Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des. 2005;11:145–55.

Google Scholar 1.

Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic Psychiatry’s Brave New World. Cell. 2020;181:24–8.

Google Scholar 1.

Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017;101:209–19.

Google Scholar 1.

Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264–355.

Google Scholar 1.

Prouzeau D, Conejero I, Voyvodic PL, Becamel C, Abbar M, Lopez-Castroman J. Psilocybin efficacy and mechanisms of action in major depressive disorder: a review. Curr Psychiatry Rep. 2022;24:573–81.

Google Scholar 1.

Lima Da Cruz RV, Leão RN, Moulin TC. Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review. Mol Med. 2024;30:244.

Google Scholar 1.

Klempin. Oppositional effects of serotonin receptors 5-HT1a, 2, and 2c in the regulation of adult hippocampal neurogenesis. Front Mol Neurosci. 2010;30:14 https://doi.org/10.3389/fnmol.2010.00014.

Google Scholar 1.

Sekssaoui M, Bockaert J, Marin P, Bécamel C. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?. Neuropsychopharmacology. 2024;49:747–56.

Google Scholar 1.

Samuels BA, Anacker C, Hu A, Levinstein MR, Pickenhagen A, Tsetsenis T, et al. 5-HT1A receptors on mature dentate gyrus granule cells are critical for the antidepressant response. Nat Neurosci. 2015;18:1606–16.

Google Scholar 1.

Segi-Nishida E. The effect of serotonin-targeting antidepressants on neurogenesis and neuronal maturation of the hippocampus mediated via 5-HT1A and 5-HT4 receptors. Front Cell Neurosci. 2017;11:142.

Google Scholar 1.

Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637–48.

Google Scholar 1.

von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine. 2023;56:101809.

Google Scholar 1.

Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78:481.

Google Scholar 1.

Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023;330:843.

Google Scholar 1.

Carhart-Harris R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402–11.

Google Scholar 1.

Svobodny G. The internationalization of Ayahuasca. J Ethnopharmacol. 2014;153:933.

Google Scholar 1.

Falchi-Carvalho M, Wießner I, Silva SRB, Maia O, Barros L, Laborde H, et al. Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial. Eur Neuropsychopharmacol. 2024;80:27–35.

Google Scholar 1.

Saavedra JM, Axelrod J. Psychotomimetic N-Methylated Tryptamines: Formation in Brain in vivo and in vitro. Science. 1972;175:1365–6.

Google Scholar 1.

Strassman RJ. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res. 1995;73:121–4.

Google Scholar 1.

Strassman RJ. Dose-Response Study of N,N-Dimethyltryptamine in Humans: II. subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994;51:98.

Google Scholar 1.

Falchi-Carvalho M, Barros H, Bolcont R, Laborde S, Wießner I, Ruschi B. Silva S, et al. The Antidepressant Effects of Vaporized N,N-Dimethyltryptamine: an open-label pilot trial in treatment-resistant depression. Psychedelic Med. 2025;3:48–52.

Google Scholar 1.

Osório FDL, Sanches RF, Macedo LR, Santos RG, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr. 2015;37:13–20.

Google Scholar 1.

Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49:655–63.

Google Scholar 1.

Jiménez-Garrido DF, Gómez-Sousa M, Ona G, Dos Santos RG, Hallak JEC, Alcázar-Córcoles MÁ, et al. Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination. Sci Rep. 2020;10:4075.

Google Scholar 1.

Falchi-Carvalho M, Palhano-Fontes F, Wießner I, Barros H, Bolcont R, Laborde S, et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology. 2025;50:895–903.

Google Scholar 1.

D’Souza DC, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacol. 2022;47:1854–62.

Google Scholar 1.

Cameron LP, Benson CJ, Dunlap LE, Olson DE. Effects of N,N-Dimethyltryptamine on rat behaviors relevant to anxiety and depression. ACS Chem Neurosci. 2018;9:1582–90.

Google Scholar 1.

Cameron LP, Benson CJ, DeFelice BC, Fiehn O, Olson DE. Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents. ACS Chem Neurosci. 2019;10:3261–70.

Google Scholar 1.

Nogueira M, Ferreira Golbert DC, Menezes R, Nóbrega de Almeida R, Galvão-Coelho NL, Siroky AN, et al. Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice. Mol Psychiatry. 2024;30:50–60. https://doi.org/10.1038/s41380-024-02655-w.

Google Scholar 1.

Winne J, Boerner BC, Malfatti T, Brisa E, Doerl J, Nogueira I, et al. Anxiety-like behavior induced by salicylate depends on age and can be prevented by a single dose of 5-MeO-DMT. Exp Neurol. 2020;326:113175.

Google Scholar 1.

Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–82.

Google Scholar 1.

Lima da Cruz RV, Moulin TC, Petiz LL, Leão RN. A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus. Front Mol Neurosci. 2018;11:312.

Google Scholar 1.

Dakic V, Minardi Nascimento J, Costa Sartore R, Maciel R, de M, de Araujo DB, et al. Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. Sci Rep. 2017;7:12863.

Google Scholar 1.

Antoniuk S, Bijata M, Ponimaskin E, Wlodarczyk J. Chronic unpredictable mild stress for modeling depression in rodents: Meta-analysis of model reliability. Neurosci Biobehav Rev. 2019;99:101–16.

Google Scholar 1.

Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4:568–72.

Google Scholar 1.

Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4:563–7.

Google Scholar 1.

Mineur YS, Belzung C, Crusio WE. Effects of unpredictable chronic mild stress on anxiety and depression-like behavior in mice. Behav Brain Res. 2006;175:43–50.

Google Scholar 1.

Blair JB, Marona-Lewicka D, Kanthasamy A, Lucaites VL, Nelson DL, Nichols DE. Thieno[3,2-b]- and Thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-Dimethyltryptamine. J Med Chem. 1999;42:1106–11.

Google Scholar 1.

Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology. 2020;167:107933.

Google Scholar 1.

Puigseslloses P, Nadal-Gratacós N, Ketsela G, Weiss N, Berzosa X, Estrada-Tejedor R, et al. Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties. Mol Psychiatry. 2024;29:2346–58.

Google Scholar 1.

Zhang J, Giesert F, Kloos K, Vogt Weisenhorn DM, Aigner L, Wurst W, et al. A powerful transgenic tool for fate mapping and functional analysis of newly generated neurons. BMC Neurosci. 2010;11:158.

Google Scholar 1.

Cheng X, Li Y, Huang Y, Feng X, Feng G, Xiong Z-Q. Pulse labeling and long-term tracing of newborn neurons in the adult subgranular zone. Cell Res. 2011;21:338–49.

Google Scholar 1.

Monteiro S, Roque S, de Sá-Calçada D, Sousa N, Correia-Neves M, Cerqueira JJ. An efficient chronic unpredictable stress protocol to induce stress-related responses in C57BL/6 mice. Front Psychiatry. 2015;6:6.

Google Scholar 1.

Nath T, Mathis A, Chen AC, Patel A, Bethge M, Mathis MW. Using DeepLabCut for 3D markerless pose estimation across species and behaviors. Nat Protoc. 2019;14:2152–76.

Google Scholar 1.

Chiara V, Kim S-Y, AnimalTA: A. highly flexible and easy-to-use program for tracking and analysing animal movement in different environments. Methods Ecol Evol. 2023;14:1699–707.

Google Scholar 1.

Jain S, LaFrancois JJ, Gerencer K, Botterill JJ, Kennedy M, Criscuolo C, et al. Increasing adult-born neurons protects mice from epilepsy. eLife. 2024;12. 1.

Myers CE, Bermudez-Hernandez K, Scharfman HE. The influence of ectopic migration of granule cells into the hilus on dentate gyrus-CA3 function. PLoS One. 2013;8:e68208.

Google Scholar 1.

Cui L, Li S, Wang S, Wu X, Liu Y, Yu W, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther. 2024;9:30.

Google Scholar 1.

Souza AC, Souza BC, França A, Moradi M, Souza NC, Leão KE, et al. 5-MeO-DMT induces sleep-like LFP spectral signatures in the hippocampus and prefrontal cortex of awake rats. Sci Rep. 2024;14:11281.

Google Scholar 1.

Wankhar W, Syiem D, Pakyntein CL, Thabah D, Sunn SE. Effect of 5-HT2C receptor agonist and antagonist on chronic unpredictable stress (CUS) - Mediated anxiety and depression in adolescent Wistar albino rat: Implicating serotonin and mitochondrial ETC-I function in serotonergic neurotransmission. Behav Brain Res. 2020;393:112780.

Google Scholar 1.

Markov DD, Novosadova EV. Chronic unpredictable mild stress model of depression: possible sources of poor reproducibility and latent variables. Biology. 2022;11:1621.

Google Scholar 1.

Strekalova T, Liu Y, Kiselev D, Khairuddin S, Chiu JLY, Lam J, et al. Chronic mild stress paradigm as a rat model of depression: facts, artifacts, and future perspectives. Psychopharmacology. 2022;239:663–93.

Google Scholar 1.

Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci. 2021;118:e2022489118.

Google Scholar 1.

Inserra A, De Gregorio D, Gobbi G. Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev. 2021;73:202–77.

Google Scholar 1.

Antila H, Ryazantseva M, Popova D, Sipilä P, Guirado R, Kohtala S, et al. Isoflurane produces antidepressant effects and induces TrkB signaling in rodents. Sci Rep. 2017;7:7811.

Google Scholar 1.

Böckmann S, Iggena D, Schreyer S, Rex A, Steiner B. Physical activity compensates for isoflurane-induced selective impairment of neuronal progenitor cell proliferation in the young adult hippocampus. Behav Brain Res. 2023;455:114675.

Google Scholar 1.

Erasso DM, Chaparro RE, Quiroga Del Rio CE, Karlnoski R, Camporesi EM, Saporta S. Quantitative assessment of new cell proliferation in the dentate gyrus and learning after isoflurane or propofol anesthesia in young and aged rats. Brain Res. 2012;1441:38–46.

Google Scholar 1.

Brown PL, Zanos P, Wang L, Elmer GI, Gould TD, Shepard PD. Isoflurane but Not Halothane Prevents and Reverses Helpless Behavior: A Role for EEG Burst Suppression?. Int J Neuropsychopharmacol. 2018;21:777–85.

Google Scholar 1.

Surget A, Belzung C. Adult hippocampal neurogenesis shapes adaptation and improves stress response: a mechanistic and integrative perspective. Mol Psychiatry. 2022;27:403–21.

Google Scholar 1.

Schloesser RJ, Manji HK, Martinowich K. Suppression of adult neurogenesis leads to an increased hypothalamo-pituitary-adrenal axis response. Neuroreport. 2009;20:553–7.

Google Scholar 1.

Yin H, Sun X, Yang K, Lan Y, Lu Z. Regulation of dentate gyrus pattern separation by hilus ectopic granule cells. Cogn Neurodyn. 2025;19:10.

Google Scholar 1.

Seguin JA, Brennan J, Mangano E, Hayley S. Proinflammatory cytokines differentially influence adult hippocampal cell proliferation depending upon the route and chronicity of administration. Neuropsychiatr Dis Treat. 2009;5:5–14.

Google Scholar 1.

Worthen RJ, Garzon Zighelboim SS, Torres Jaramillo CS, Beurel E. Anti-inflammatory IL-10 administration rescues depression-associated learning and memory deficits in mice. J Neuroinflammation. 2020;17:246.

Google Scholar 1.

Fang S, Wu Z, Guo Y, Zhu W, Wan C, Yuan N, et al. Roles of microglia in adult hippocampal neurogenesis in depression and their therapeutics. Front Immunol. 2023;14:1193053.

Google Scholar 1.

Da Silva Joaquim L, Da Rosa LR, Strickert Y, Machado RS, Lanzzarin E, Bernardes G, et al. Ayahuasca reverses ischemic stroke-induced neuroinflammation and oxidative stress. Behav Brain Res. 2025;485:115521.

Google Scholar 1.

De Camargo RW, Joaquim L, Machado RS, De Souza Ramos S, Da Rosa LR, De Novais Junior LR, et al. Ayahuasca Pretreatment Prevents Sepsis-Induced Anxiety-Like Behavior, Neuroinflammation, and Oxidative Stress, and Increases Brain-Derived Neurotrophic Factor. Mol Neurobiol. 2025;62:5695–719.

Google Scholar 1.

Jones KL, Zhou M, Jhaveri DJ. Dissecting the role of adult hippocampal neurogenesis towards resilience versus susceptibility to stress-related mood disorders. NPJ Sci Learn. 2022;7:16.

Google Scholar 1.

Effinger DP, Quadir SG, Ramage MC, Cone MG, Herman MA. Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. Transl Psychiatry. 2023;13:119.

Google Scholar 1.

Vohra HZ, Saunders JM, Jaster AM, de la Fuente Revenga M, Jimenez J, Fernández-Teruel A, et al. Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6/SvEv mice. Psychopharmacology. 2022;239:1649–64.

Google Scholar 1.

Nigri AW, Falcão de Arruda I, Maia CGF, Tófoli LF, Carezzato F. Psychedelics for substance use disorders: are women being addressed? A scoping review. Int J Drug Policy. 2025;145:104960.

Google Scholar 1.

Cohen ZZ, Blest-Hopley G. Females in psychedelic research: a perspective for advancing research and practice. ACS Pharmacol Transl Sci. 2025;8:1837–46.

Google Scholar

Download references